Loading
A phase 1/2 trial of Datopotamab deruxtecan in non-small-cell lung cancer and triple-negative breast cancer, run by AstraZeneca, active and no longer recruiting.
A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) is a phase 1/2 interventional study registered as NCT05460273 by AstraZeneca, with 119 participants enrolled, started 2022-07-11 and due to reach its primary completion in 2023-11-07. Interventions recorded: Datopotamab Deruxtecan (Dato-DXd). Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
119 enrolled.
95% CI 23.4 to 45.4; Figures from the ClinicalTrials.gov results section (first posted 2025-06-13), not from a publication · 95% CI 29.3 to 61.5
Source95% CI 10.7 to NA; Figures from the ClinicalTrials.gov results section (first posted 2025-06-13), not from a publication · 95% CI 13.8 to 20.4
SourceShares Metastatic triple-negative breast cancer, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Daiichi Sankyo, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Datopotamab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Daiichi Sankyo, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Daiichi Sankyo, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC) and the tag pipeline.